Thanks for that study barsax. 37 million American's with CKD and 700 million world wide. Looks like there is enough room in that market for more than a couple of competetors.

https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease.html 

tada